| Jason Schend, DO | |
|
1321 W 22nd St, Sioux Falls, SD 57105-1502 | |
| (605) 404-4000 | |
| Not Available |
| Full Name | Jason Schend |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 9 Years |
| Location | 1321 W 22nd St, Sioux Falls, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861833774 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 14400 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Usd Medical Center | Sioux falls, SD | Hospital |
| Mercy Health Hackley Campus | Muskegon, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center | 8325950215 | 707 |
News Archive
New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.
Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.
McGill researchers have identified a small region in the genome that conclusively plays a role in the development of psychiatric disease and obesity. The key lies in the genomic deletion of brain-derived neurotrophic factor, or BDNF, a nervous system growth factor that plays a critical role in brain development.
Low blood levels of immune cells called lymphocytes, in combination with higher levels of inflammation on PET/CT scans, are indicators of active sarcoidosis - an inflammatory disease that attacks multiple organs, particularly the lungs and lymph nodes - which disproportionately affects African Americans.
Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.
› Verified 3 days ago
| Entity Name | Sanford Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821017880 PECOS PAC ID: 8325950215 Enrollment ID: O20040115000388 |
News Archive
New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.
Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.
McGill researchers have identified a small region in the genome that conclusively plays a role in the development of psychiatric disease and obesity. The key lies in the genomic deletion of brain-derived neurotrophic factor, or BDNF, a nervous system growth factor that plays a critical role in brain development.
Low blood levels of immune cells called lymphocytes, in combination with higher levels of inflammation on PET/CT scans, are indicators of active sarcoidosis - an inflammatory disease that attacks multiple organs, particularly the lungs and lymph nodes - which disproportionately affects African Americans.
Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Schend, DO Po Box 5074, Sioux Falls, SD 57117-5074 Ph: (605) 328-6585 | Jason Schend, DO 1321 W 22nd St, Sioux Falls, SD 57105-1502 Ph: (605) 404-4000 |
News Archive
New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.
Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.
McGill researchers have identified a small region in the genome that conclusively plays a role in the development of psychiatric disease and obesity. The key lies in the genomic deletion of brain-derived neurotrophic factor, or BDNF, a nervous system growth factor that plays a critical role in brain development.
Low blood levels of immune cells called lymphocytes, in combination with higher levels of inflammation on PET/CT scans, are indicators of active sarcoidosis - an inflammatory disease that attacks multiple organs, particularly the lungs and lymph nodes - which disproportionately affects African Americans.
Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.
› Verified 3 days ago